{"name":"Viatris Innovation GmbH","slug":"viatris-innovation-gmbh","ticker":"","exchange":"","domain":"viatrisinnovationgmbh.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AC-076 for s.c. administration","genericName":"AC-076 for s.c. administration","slug":"ac-076-for-s-c-administration","indication":"Other","status":"phase_1"},{"name":"ACT-246475","genericName":"ACT-246475","slug":"act-246475","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"AC-076 for s.c. administration","genericName":"AC-076 for s.c. administration","slug":"ac-076-for-s-c-administration","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ACT-246475","genericName":"ACT-246475","slug":"act-246475","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPOUlxZjB4cG1wSmpjSWZyNU8zaDdSZVdmaHlUNnpaVnR0WTJBWHlSYVRCZnJSa1JobjVvLWktREJ0TnhnYzZ2U3NvblFpUW5jdF9pYm9hNlk0TGlrVEVpaE5vblVMbWR2b25uXzhPZzFCZmtRcUpiVDc3RFFWaXNhZDlPYkI4RlVJZ1lYYVA5U0J0OGN4Y1FhbWdFZ0lkMmg3OHpIbUk3RXhJaEIwanFv?oc=5","date":"2026-02-26","type":"pipeline","source":"Fierce Pharma","summary":"Viatris to cut 10% of workforce in 3-year overhaul, discloses fire at India plant - Fierce Pharma","headline":"Viatris to cut 10% of workforce in 3-year overhaul, discloses fire at India plant","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQbHdSaEI3OEFFODZtOXB1SDRxRGlDWEI0dzFEM2hWN3FKSUVWcWllZHpoVjItOWlFcFRGaDh0TmJwYkNNcnBNSDR3Zkxid1lsSjNSLWZSRmZ3Q0pVeWpZeW15d0xycGtRU0ZQLU9wY1ZkUFo3T01DaW5kYXJwNjhhMkRyWkcwamNmTk03MnprOVpRVExyTk5QOGJfM2t5azZ5Q3Z3X3Z5XzNvUzNYeDIzWlMtcWFySnc?oc=5","date":"2025-11-14","type":"regulatory","source":"European Medicines Agency (EMA)","summary":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 November 2025 - European Medicines Agency (EMA)","headline":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 November 2025 - European Medicin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxPUngtcFJLQ2VKSnZyeWR1bERZTDMyQ21vaWppU1dnSVJZSWFrTUdsNk1qb1hacmVzQVNZT1lSNE9FVk9CeWllX1BJM3Z3cGZDMUhnZjUzUWEtbm9Zc3BkUi12M2tMdGpxbFN4VFZFMXRyQWUzRUJ2RDVxQlU5OU1yLVZtaWhaMDRkYnltMU5WNHdiTGNuUXFQTW1lNlZvLVFfM254N0NQZkEweS00UjJGUFEtN0Fvb1RBeTQwX2ttd3AyRFdma2gxSlg4aHVtaW1Sd0M2c0ZSdXVFQzFn?oc=5","date":"2024-02-28","type":"deal","source":"prnewswire.com","summary":"Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration - prnewswire.com","headline":"Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPcm5kWlRQUmM1MkxJSlhwSC1BOEpIWDh6VlZxTVZqdHZPeHItQi1EemxVUTVBRDkyN1JtTmJiekZkTGlraWNUa0JuUzZGekg0UG9DaWVSTGwxamU4ZnN0VGF5OVpBaWJIY2pQd3lwNzBPa1doM2JzTE1BNmUwSnBzUzc2Q3JVWndFb0RBM3NzWi1xX29GSDFGcmNJMy1GWnBuQlN1YmZyU2FJeFg4S1Q3SUs5Vl9zQQ?oc=5","date":"2019-11-12","type":"pipeline","source":"Fierce Pharma","summary":"Pfizer's Upjohn and Mylan will become Viatris. Wait, haven't we heard that name before? - Fierce Pharma","headline":"Pfizer's Upjohn and Mylan will become Viatris. Wait, haven't we heard that name before?","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}